MARKET

INSM

INSM

Insmed Inc
NASDAQ
21.54
-0.33
-1.51%
After Hours: 21.54 0 0.00% 17:00 09/30 EDT
OPEN
21.88
PREV CLOSE
21.87
HIGH
22.47
LOW
21.48
VOLUME
741.43K
TURNOVER
0
52 WEEK HIGH
34.44
52 WEEK LOW
16.41
MARKET CAP
2.58B
P/E (TTM)
-6.1355
1D
5D
1M
3M
1Y
5Y
Are Investors Undervaluing Insmed Incorporated (NASDAQ:INSM) By 47%?
Does the September share price for Insmed Incorporated ( NASDAQ:INSM ) reflect what it's really worth? Today, we will...
Simply Wall St. · 09/18 13:55
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to 10 new employees. In accordance with NASDAQ Listing ...
PR Newswire · 09/07 12:00
Insmed To Present at Two September Conferences
Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present at the following investor events:
PR Newswire · 09/06 12:00
Insmed's Return On Capital Employed Insights
 
Benzinga · 08/18 14:02
Insider Sell: Insmed
Insider Sell: Insmed
MT Newswires · 08/11 10:34
Investors bid Insmed (NASDAQ:INSM) up US$686m despite increasing losses YoY, taking five-year CAGR to 19%
The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But when you pick a company...
Simply Wall St. · 08/08 17:23
Insmed rises 16% on better-than-expected Q2 result
Insmed (NASDAQ:INSM) is trading 16% highe...
Seekingalpha · 08/04 14:45
Insmed Earlier Reported Q2 EPS $(0.80) Beats $(0.89) Estimate, Sales $65.22M Beat $59.41M Estimate
Insmed (NASDAQ:INSM) reported quarterly losses of $(0.80) per share which beat the analyst consensus estimate of $(0.89) by 10.11 percent. This is a 12.09 percent increase over losses of $(0.91) per share from the same
Benzinga · 08/04 13:55
More
About INSM
Insmed Incorporated is a biopharmaceutical company engaged in providing ARIKAYCE (amikacin liposome inhalation suspension) product, which is used for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its clinical-stage pipeline includes brensocatib and treprostinil palmitil inhalation powder (TPIP). Brensocatib is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1, which is developing for the treatment of patients with bronchiectasis, cystic fibrosis (CF) and other neutrophil-mediated diseases, including chronic rhinosinusitis without nasal polyps (CRS) and hidradenitis suppurativa (HS). TPIP is an inhaled formulation of the treprostinil prodrug treprostinil palmitil which may offer a differentiated product profile for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

Webull offers kinds of Insmed Incorporated stock information, including NASDAQ:INSM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, INSM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading INSM stock methods without spending real money on the virtual paper trading platform.